PharmaLex Expands Nordic Presence, Merges with DRA Consulting
Partnership adds technological offerings to PharmaLex’s repertoire
PharmaLex Group, a specialized services source for the pharma, biotech, and medtech industries, has announced a merger with Finnish consulting company, DRA Consulting. The consulting firm will become part of the broader PharmaLex Nordic region after the merger, making the Nordics the fourth largest market for PharmaLex.
The merger adds several state-of-the-art technology solutions to PharmaLex’s growing digital platform, including robotics capabilities for pharmacovigilance, automation for writing sections of the CMC, and tools to harmonize some regulatory tasks.
“The merger is integral to helping us remain competitive in the future and to increasing our global market share. Together, with PharmaLex, we can achieve a stronger presence in the Nordic countries and globally giving our clients access to broader expertise in multiple markets,” notes Kaija Korpiaho-Haga, CEO, partner, and co-founder of DRA Consulting.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
